4D-150 in Patients With Diabetic Macular Edema
Diabetic Macular Edema, Diabetic Retinopathy
About this trial
This is an interventional treatment trial for Diabetic Macular Edema focused on measuring Retinal gene therapy, Intravitreal gene therapy, DME, SPECTRA
Eligibility Criteria
Inclusion Criteria: ≥18 years of age Type I or Type II diabetes mellitus with macular thickening secondary to DME involving the center of the fovea Demonstrate clinical response to on-study aflibercept injection in the study eye. Decreased visual acuity attributable primarily to DME BCVA in the study eye between 25 and 83 ETDRS letters, inclusive (~20/320 and 20/25, respectively) at Screening Study eye amenable to IVT injection Sufficient clear ocular media, pupil dilation and fixation in the study eye to permit adequate imaging; ability to perform tests of visual and retinal function and structure; and ability to comply with other protocol-specified procedures Provide written informed consent Exclusion Criteria: Macular edema in the study eye considered to be secondary to a cause other than DME Systemic anti-VEGF treatment (e.g. sunitinib, bevacizumab, pazopanib) within 6 months, or anticipated need for systemic anti-VEGF therapy during study participation Systemic corticosteroids (oral, intravenous, intramuscular, intra-articular) or other immunosuppressive medications within 3 months Received an investigational drug, agent, device, or therapy (ocular or non-ocular) in the 6 months or at least 5 half-lives (whichever is longer) prior to Screening Prior gene therapy (ocular or non-ocular) and/or ocular stem cell therapy in either eye Any concurrent ocular condition in the study eye that is likely to require surgical intervention (e.g. cataract surgery) during the 2 year (104 week) study duration Note: Other inclusion/exclusion criteria apply.
Sites / Locations
- National Ophthalmic Research InstituteRecruiting
- Cumberland Valley Retina ConsultantsRecruiting
- Verum Research, LLCRecruiting
- Erie Retina ResearchRecruiting
- Austin Clinical ResearchRecruiting
- Piedmont Eye CenterRecruiting
- Emanuelli Research and Development CenterRecruiting
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
Arm 5
Arm 6
Experimental
Experimental
Active Comparator
Experimental
Experimental
Active Comparator
4D-150 Part 1 Dose Confirmation Dose Level 1
4D-150 Part 1 Dose Confirmation Dose Level 2
4D-150 Part 1 Dose Confirmation Control
4D-150 Part 2 Dose Expansion Dose Level 1
4D-150 Part 2 Dose Expansion Dose Level 2
4D-150 Part 2 Dose Expansion Control
4D-150 will be administered at the assigned dose level as a single dose IVT injection on Day 1.
4D-150 will be administered at the assigned dose level as a single dose IVT injection on Day 1.
Aflibercept will be administered PRN.
4D-150 will be administered at the assigned dose level as a single dose IVT injection on Day 1.
4D-150 will be administered at the assigned dose level as a single dose IVT injection on Day 1.
Aflibercept at a fixed regimen will be administered.